For example, one study observed that after i.v. administration of MSC-loaded IL-12 (MSC/IL-12) in tumor-bearing mice, tumor growth was inhibited, the number of metastases significantly decreased, blood vessel density decreased, and the number of anticancer M1 macrophages and CD8+ T lymphocytes in the tumors increased, without systemic toxicity [237]. This evidence concerns the gene CD8A and neoplasm.